VRTX in the 13F filings
Vertex Pharmaceuticals Inc · CUSIP 92532F100
- Quarter end
- 31 Dec 2024
- the date the book describes
- Filed
- 5 Nov 2026
- latest of these filings; the earliest 31 Jan 2025
- Managers listing it
- 26
- at least, of 95 tracked, among listed positions
- Comparable managers
- 94
- filed both Q3 2024 and Q4 2024; 22 listed it in both
- Shares listed
- 70,699,113
- combined, among listed positions
- Reported value
- $28.5bn
- combined, at the quarter end
Among the 94 comparable managers: 14 buyers (opened or added shares) and 13 sellers (trimmed or exited), at least, among listed positions. Their net change in shares is not known from listed positions, because at least one of them lists it in only one of the two quarters.
Managers listing VRTX in Q4 2024
26 of 26 holders
Largest increases and reductions, by shares
Increases
- Capital World Investorsexisting position · 28,325,695 shares now+1,514,993
- Capital Research Global Investorsexisting position · 10,428,951 shares now+1,426,746
- Wellington Management Group LLPexisting position · 5,916,084 shares now+1,117,214
- Janus Henderson Group Ltdexisting position · 2,833,889 shares now+317,058
- D. E. Shaw & Co.existing position · 265,684 shares now+127,276
Reductions
- AllianceBernstein LPexisting position · 3,920,020 shares now-3,452,747
- Fidelity (FMR LLC)existing position · 9,219,046 shares now-1,305,967
- MFS Investment Managementexisting position · 2,288,498 shares now-617,207
- AQR Capital Management LLCexisting position · 245,785 shares now-235,076
- Renaissance Technologies LLCexisting position · 1,397,209 shares now-234,284
New positions and exits
New (2)
Exited (1)
- Egerton Capital UK LLPwas $58m
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q2 2013 | 13 | $5.0bn | n.a. | n.a. |
| Q3 2013 | 12 | $4.6bn | n.a. | n.a. |
| Q4 2013 | 9 | $4.8bn | n.a. | n.a. |
| Q1 2014 | 11 | $4.9bn | n.a. | n.a. |
| Q2 2014 | 11 | $7.3bn | n.a. | n.a. |
| Q3 2014 | 14 | $9.0bn | n.a. | n.a. |
| Q4 2014 | 15 | $9.3bn | n.a. | n.a. |
| Q1 2015 | 21 | $9.2bn | n.a. | n.a. |
| Q2 2015 | 23 | $9.4bn | n.a. | n.a. |
| Q3 2015 | 22 | $8.3bn | n.a. | n.a. |
| Q4 2015 | 19 | $10.2bn | n.a. | n.a. |
| Q1 2016 | 18 | $6.8bn | n.a. | n.a. |
| Q2 2016 | 13 | $7.5bn | n.a. | n.a. |
| Q3 2016 | 14 | $7.7bn | n.a. | n.a. |
| Q4 2016 | 14 | $6.3bn | n.a. | n.a. |
| Q1 2017 | 21 | $9.5bn | n.a. | n.a. |
| Q2 2017 | 24 | $11.0bn | n.a. | n.a. |
| Q3 2017 | 28 | $12.6bn | n.a. | n.a. |
| Q4 2017 | 24 | $12.2bn | n.a. | n.a. |
| Q1 2018 | 24 | $13.3bn | n.a. | n.a. |
| Q2 2018 | 27 | $14.0bn | n.a. | n.a. |
| Q3 2018 | 26 | $15.7bn | n.a. | n.a. |
| Q4 2018 | 27 | $14.6bn | n.a. | n.a. |
| Q1 2019 | 26 | $17.0bn | n.a. | n.a. |
| Q2 2019 | 24 | $17.0bn | n.a. | n.a. |
| Q3 2019 | 25 | $16.0bn | n.a. | n.a. |
| Q4 2019 | 29 | $20.0bn | n.a. | n.a. |
| Q1 2020 | 27 | $20.9bn | n.a. | n.a. |
| Q2 2020 | 27 | $23.4bn | n.a. | n.a. |
| Q3 2020 | 31 | $21.9bn | n.a. | n.a. |
| Q4 2020 | 30 | $18.4bn | n.a. | n.a. |
| Q1 2021 | 31 | $15.4bn | n.a. | n.a. |
| Q2 2021 | 30 | $12.7bn | n.a. | n.a. |
| Q3 2021 | 35 | $10.1bn | n.a. | n.a. |
| Q4 2021 | 28 | $12.4bn | n.a. | n.a. |
| Q1 2022 | 23 | $16.1bn | n.a. | n.a. |
| Q2 2022 | 25 | $18.1bn | n.a. | n.a. |
| Q3 2022 | 22 | $18.4bn | n.a. | n.a. |
| Q4 2022 | 28 | $18.4bn | n.a. | n.a. |
| Q1 2023 | 26 | $21.4bn | n.a. | n.a. |
| Q2 2023 | 27 | $24.7bn | n.a. | n.a. |
| Q3 2023 | 33 | $24.3bn | n.a. | n.a. |
| Q4 2023 | 32 | $28.6bn | 16 | 16 |
| Q1 2024 | 31 | $29.8bn | 16 | 19 |
| Q2 2024 | 29 | $33.4bn | 12 | 18 |
| Q3 2024 | 27 | $33.5bn | 17 | 10 |
| Q4 2024 | 26 | $28.5bn | 14 | 13 |
| Q1 2025 | 21 | $35.4bn | 10 | 11 |
| Q2 2025 | 21 | $32.3bn | 11 | 11 |
| Q3 2025 | 22 | $25.9bn | 13 | 10 |
| Q4 2025 | 26 | $31.8bn | 19 | 20 |
| Q1 2026 | 25 | $31.8bn | 17 | 21 |
| Q2 2026 | 26 | $34.6bn | 21 | 17 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
VRTX and LLY →VRTX and JNJ →VRTX and GILD →Choose a stock to compare with VRTX →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own VRTX, latest filings →Back to the 13F Explorer →